This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ELCC 2019

European Lung Cancer Congress 2019

At the 2019 ELCC meeting, Boehringer Ingelheim hosted a symposium and presented recent findings in the treatment of lung cancer.

10–13 April 2019
Palexpo Exhibition Centre, Geneva, Switzerland

Symposium: Sequencing algorithms in non-small cell lung cancer

At this symposium, a faculty of renowned experts discussed sequential therapy in EGFR mutation-positive NSCLC and in non-oncogene-addicted non-squamous NSCLC. Please see below for video interviews with the faculty and downloads of their presentations.

        Vanesa Gregorc

Chair; Sequencing algorithms in NSCLC

Presenter(s): Vanesa Gregorc
        Nicolas Girard

Prolonging the chemotherapy-free period in EGFRM+ NSCLC

Presenter(s): Nicolas Girard
        Martin Reck

Recent changes and sequencing strategies in non−mutated, non-squamous advanced NSCLC

Presenter(s): Martin Reck
        Nir Peled

Treatment strategies in EGFRM+ NSCLC

Presenter(s): Nir Peled
Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types

Publications on our emerging data and the investigator-initiated VARGADO study were also presented at ELCC.

Thursday 11th April 2019
Afatinib* in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: an interim analysis of a Phase IIIB trial
Author(s): Passaro et al.
Oral Presentation
Tumour Type(s): NSCLC
Presentation Number: 115O
Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Author(s): Grohe et al.
Oral Presentation
Tumour Type(s): NSCLC
Presentation Number: 119O
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: June 2019